The possible implication of clusterin-dependent serum cholesterol trafficking in Alzheimer's disease

Current Neurobiology

Volumn 1, Issue 1, 2010, Pages 14-20

  Pajak, Beata ^a   Orzechowski, Arkadiusz ^a,b   Gajkowska, Barbara ^a  

^a MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^b WARSAW UNIVERSITY OF LIFE SCIENCES   (Poland)

Author keywords

Alzheimer's disease; Atherosclerosis; Cholesterol; Glycoprotein; Hypercholesterolemia; Neuropathies

Indexed keywords

ALPHA SECRETASE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; CHOLESTEROL; CLUSTERIN; GAMMA SECRETASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ALZHEIMER DISEASE; APOPTOSIS; ASTROCYTE; BLOOD BRAIN BARRIER; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; DEMENTIA; DISEASE ASSOCIATION; DRUG EFFECT; HUMAN; HYPERCHOLESTEROLEMIA; NERVE CELL; PATHOGENESIS; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; REVIEW;

EID: 79952460677     PISSN: 09759042     EISSN: 09761705     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Bettuzzi S, Pucci S. Clusterin. Advances in Cancer Research 104, Elsevier, 2009.
2. Purello M, Bettuzzi S, Di Pietro C, Mirabile E, Di Blasi M, Rimini R, Grzeschik KH, Ingletti C, Corti A, Sichel G. The gene for SP 40,40, human homolog of the rat sulfated glycoprotein 2, rat clusterin and rat testosterone-repressed prostate message 2, maps to chromosome 8. Genomics 1991; 10: 151-156.
3. Jones SE, Jomary C. Clusterin. Int J Biochem Cell Biol 2002; 34: 427-431.
4. Nilselid AM, Davidsson P, Nagga K, Andreasen N, Fredman P, Blennow K. Clusterin in cerebrospinal fluid: analysis of carbohydrates and quantification of native and glycosylated forms. Neurochem Int 2006; 48: 718-728.
5. Nuutinen T, Suuronen T, Kauppinen A, Salminen A. Clusterin: a forgotten player in Alzheimer's disease. Brain Res Rev 2009 (in press).
6. MeGeer PL, Kawamata T, Walker DG. Distribution of clusterin in Alzheimer brain tissue. Brain Res 1992; 579(2): 337-341.
7. Oda T, Pasinetti GM, Osterburg HH, Anderson C, Johnson SA, Finch CE. Purification and characterization of brain clusterin. Biochem Biophys Res Comun 1994; 204 (3):1131-1136.
8. Bertrand P, Poirier J, Oda T, Finch CE, Pasinetti GM. Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. Brain Res Mol Brain Res 1995; 33 (1): 174-178.
9. Duguid JR, Bohmot CW, Ningai L, Toutellotte WW. Changes in brain gene expression shared by scrapie and Alzheimer's disease. Proc Natl Acad Sci USA 1989; 86: 7260-7264.
10. May PC, Lampert-Etchells M, Johnson SA, Poirier J, Masters JN, Finch CE. Dynamics of gene expression for a hippocampal glycoprotein elevated in Alzheimer's disease and in response to experimental lesions in rat. Neuron 1990; 5: 831-839.
11. Tycko B, Feng L, Nguyen L, Francis A, Hays A, Chung WY, Tang MX, Stern Y, Sahota A, Hendrie H, Mayeux R. Polymorphisms in the human apolipoprotein-J/clusterin gene: ethnic variation and distribution in Alzheimer's disease. Hum Genet 1996; 98: 430-436.
12. th Anniversary Annual Meeting in Chicago, 2008.
13. Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint R, Sambamurti K, Duff K, Pappolla MA. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 2000; 7 (4): 321-331.
14. Dieter EJ, Lowin B, Peitsch MC, Bottcher A, Schmitz G, Tschopp J. Clusterin (complement lysis inhibitor) forms a high density lipoprotein complex with apolipoprotein A-I in human plasma. J Biol Chem 1991; 266 (17): 11030-11036.
15. Navab M, Hama-Levy S, Van Lenten BJ, Fonarow GC, Cardinez CJ, Castellani LW, Brennan ML, Lusis AJ, Fogelman AM. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest 1997; 99: 2005-2019.
16. Zlokovic BV, Martel CL, Matsubara E, McComb JG, Zheng G, McCluskey RT, Frangione B, Ghiso J. Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid β at the blood-brain and blood-cerebrospinal fluid barriers. J Biol Chem 1996; 93: 4229-4234.
17. Fisher CE, Howie SEM. The role of megalin (LRP-2/Gp330) during development. Dev Biol 2006; 296: 279-297.
18. LaFerla FM, Troncoso JC, Strickland DK, Kawas CH, Jay G. Neuronal cell death in Alzheimer's disease correlates with apoE uptake and intracellular Abeta stabilization. J Clin Invest 1997; 100 (2): 310-320.
19. Assemat E, Vinot S, Gofflot F, Linsel-Nitschke P, Illien F, Chatelet F, Verroust P, Louvet-Vallee S, Rinninger F, Kozyarki R. Expression and the role of cubilin in the internalization of nutrients during the peri-implantation development of the rodent embryo. Biol Reprod 2005; 72 (5):1079-1086.
20. Wolozin B. Cholesterol and the biology of Alzheimer's disease. Neuron 2004; 41: 7-10.
21. Selkoe DJ. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 1999; 399 (supp1): A23-A31.
22. Cao X, Sudhof TC. A transcriptionally active complex of APP with Fe65 and histone acetyltransferease Tip60. Science 2001; 293: 115-120.
23. Cordy JM, Hussain I, Dingwall C, Hooper NM, Turner AJ. Exclusively targeting β-secretase to lipid rafts by GPI-anchor addition up-regulates b-site processing of the amyloid precursor protein. Proc Natl Acad Sci USA 2003; 100 (20): 11735-11740.
24. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000; 356: 1627-1631.
25. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000; 57: 1439-1443.
26. Yerbury JJ, Poon S, Meehan S, Thompson B, Kumita JR, Dobson CM, Wilson MR. The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures. FASEB J 2007; 21: 2312-2322.
27. Matsubara E, Soto C, Governale S, Frangione B, Ghiso J. Apolipoprotein J and Alzheimer's amyloid solubility. Biochem J 1996; 316: 671-679.
28. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apoplipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jacob disease. Brain Res 1991; 541: 163-166.
29. Rajendran L, Honsho M, Zhan MR, Keller P, Geiger KD, Verkade P, Somons K. Alzheimer's disease β-amyloid pep-tides are released in asoociation with exosomes. Proc Natl Acad Sci USA 2006; 103 (30): 11172-11177.
30. Zhu YJ, Lin H, Lal R. Fresh and nonfibrillar amyloid β protein (1-40) induces rapid cellular degeneration in aged human fibroblasts: evidence for AβP-channel-mediated cellular toxicity. FASEB J 2000; 14: 1244-1254.
31. Fonfria E, Marshall CB, Boyfield I, Skaper SD, Hughes JP, Owen DE, Zhang W, Miller BA, Benham CD, McNulty S. Amyloid β-peptide (1-42) and hydrogen peroxide-induced toxicity are mediated by TRPM2 in rat primary striatal cultures. J Neurochem 2005; 95: 715-723.
32. Orzechowski A, Jank M, Gajkowska B, Sadkowski T, Godlewski MM. A novel antioxidant-inhibited dexamethasone-mediated and caspase-3-independent muscle cell death. Ann N Y Acad Sci 2004; 1010, S:205-208.
33. Leskov KS, Klokov DY, Li J, Kinsella TJ, Boothman DA. Synthesis and functional analyses of nuclear clusterin, a cell death protein. J Biol Chem 2003; 278 (13): 11590-11600.
34. Pajak B, Orzechowski A. Clusterin: the missing link in the calcium-dependent resistance of cancer cells to apoptogenic stimuli. Post Hig Med Dosw 2006; 60: 45-51.